Valentis May Sell Itself

Valentis Inc. (VLTS) stock collapsed over news that the company's peripheral arterial disease treatment VLTS 934 failed a Phase IIb clinical trial. The biotechnology company is considering selling itself. The stock plummeted $2.63 to close at 70 cents.